Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Sep;81(3):e33-e34.
doi: 10.1016/j.jinf.2020.06.072. Epub 2020 Jun 30.

Elevation of ACE2 as a SARS-CoV-2 entry receptor gene expression in Alzheimer's disease

Key-Hwan Lim  1 , Sumin Yang  1 , Sung-Hyun Kim  1 , Jae-Yeol Joo  2
Affiliations
Comment

Elevation of ACE2 as a SARS-CoV-2 entry receptor gene expression in Alzheimer's disease

Key-Hwan Lim et al. J Infect. 2020 Sep.
No abstract available

Keywords: Ace2; Alzheimer's disease; Genome-wide association study; Sars-cov-2.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest All financial and non-financial competing interests.

Figures

Fig 1
Fig. 1
Ace2 gene expression profiling in AD patient brain. (A) Gene expression is quantified by total RNA-seq. Extracted total RNAs were synthesized to cDNA using random primers. Gene expression profiling was based on Agilent GeneSpring analysis; image was generated by the FASTQ illumine package bcl2faseq. Single- or paired-end reads were calculated from next generation sequencing (NGS). (B) Visualization of Ace1 and Ace2 gene expression in the UCSC genome browser. Representative UCSC genome browser tracks of Ace1 and Ace2 are shown for cortex and whole blood. Total RNA-seq covered for whole Ace1 and Ace2 gene expression region and mapping each sequencing reads. Ace2 fragments per kb per million reads (FPKM) values are significantly increased in 5xFAD cortex. Ace1 FPKM values are increased in AD model blood. There was no significant change of Ace1 in 5xFAD cortex. Ace2 showed very small amount of gene expression both WT and 5xFAD. The FPKM values for each gene were calculated with the Cufflinks package. (C) Analysis of Ace1 and Ace2 gene expression profile from human brain microarray dataset in AD patients. Gene expression analysis in hippocampus showed that Ace2 gene expression levels are elevated in the severe patient group compared to healthy group (135%, 148%, 164%, respectively). On the other hand, Ace1 gene expression levels decreased by 32% in incipient patients, and then return to normal levels in moderate and severe patient groups (111% and 116%, respectively). Control group n = 9, incipient group n = 7, moderate group n = 8, severe group n = 7. (D) Analysis of Ace1 and Ace2 gene expression profile from human PBMCs microarray dataset in AD patients. Gene expression analysis result in human PBMCs showed that Ace1 gene was expressed at a level of 39% compared to the normal groups, whereas Ace2 gene was expressed at a level of 69% compared to the normal groups. Normal patients group n = 3, Mild patients group n = 3, Severe patients group n = 3. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
See this image and copyright information in PMC

Comment on

References

    1. Liu K., Chen Y., Lin R., Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020;80(6):e14–ee8. PubMed PMID: 32171866. - PMC - PubMed
    1. Fu L., Wang B., Yuan T., Chen X., Ao Y., Fitzpatrick T. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect. 2020;80(6):656–665. - PMC - PubMed
    1. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565–574. - PMC - PubMed
    1. Hou Y., Dan X., Babbar M., Wei Y., Hasselbalch S.G., Croteau D.L. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol. 2019;15(10):565–581. - PubMed
    1. Masters C.L., Bateman R., Blennow K., Rowe C.C., Sperling R.A., Cummings J.L. Alzheimer's disease. Nat Rev Dis Primers. 2015 Oct 15;1:15056. - PubMed

Substances